HDAC1在肺癌中的潜在作用机制及研究进展
Potential Mechanisms and Research Advances of HDAC1 in Lung Cancer
摘要
Abstract
Lung cancer is the malignant tumor with the highest incidence and mortality rate worldwide.The current treatment methods have limited efficacy,and the prognosis of patients is poor.There is an urgent need to explore new therapeutic targets and strategies.Epigenetic modification disorders are closely related to the occurrence and development of tumors.Among them,histone deacetylase 1(HDAC1),as a key epigenetic regulatory molecule,participates in the regulation of biological pro-cesses such as cell proliferation,differentiation,and apoptosis.HDAC1 is highly expressed in lung cancer,and its expression level is closely related to the malignancy degree,clinical stage,and poor prognosis of lung cancer.Abnormal activation of HDAC1 is also one of the core factors for the resistance of lung cancer to chemotherapy,targeted therapy,and immunotherapy.The development of HDAC1 inhibitors provides a new direction for the treatment of lung cancer,and the combination with chemotherapy,targeted therapy,and immunotherapy can significantly enhance the synergistic anti-tumor effect.This article systematically reviews the structural characteristics and physiological functions of HDAC1,deeply explores its regulatory mechanism in lung cancer,elabo-rates on its association with lung cancer resistance,and summarizes the research and development progress,clinical trial status,and challenges of HDAC1 inhibitors,with the aim of providing new ideas for the precise treatment of lung cancer.关键词
肺肿瘤/HDAC1/表观遗传修饰/HDAC1抑制剂Key words
Lung neoplasms/HDAC1/Epigenetic modifications/HDAC1 inhibitors引用本文复制引用
刘明珠,王传林,胡瑾,赵光强,黄云超,周岚..HDAC1在肺癌中的潜在作用机制及研究进展[J].中国肺癌杂志,2026,29(4):302-309,8.基金项目
This paper was supported by the grants from National Natural Science Foundation of China(No.82360562,to Yunchao HUANG),Postgraduate Innovation Fund of Kunming Medical University(No.2025S113,to Mingzhu LIU),Medical Quality(Evidence-Based)Management Research Project of the National Institute of Hospital Administration,National Health Commission of the People's Republic of China(No.YLZLXZ24K007,to Lan ZHOU),Yunnan Provincial Innovation Team for Thoracic Tumor Prevention and Treatment Research(No.202405AS350015,to Guangqiang ZHAO)and Yunnan Provincial Department of Education Science Research Fund(No.2026Y0406,to Chuanlin WANG). 本文受国家自然科学基金项目(No.82360562)、昆明医科大学研究生创新基金项目(No.2025S113)、国家卫生健康委医院管理研究所医疗质量(循证)管理研究项目(No.YLZLXZ24K007)、云南省胸部肿瘤防治研究创新团队项目(No.202405AS350015)和云南省教育厅科学研究基金项目(No.2026Y0406)资助 （No.82360562,to Yunchao HUANG）
